Selank

Selank is a synthetic heptapeptide built from tuftsin, an immunomodulatory tetrapeptide fragment of the immunoglobulin G heavy chain, extended with a Pro-Gly-Pro sequence that resists enzymatic degradation. That dual heritage — immune peptide plus stabilising tail — is why its literature runs in two directions at once.

The anxiolytic strand is the larger one. Animal work reports reduced anxiety-related behaviour in standard paradigms, with published mechanisms including modulation of GABAergic signalling and changes in the expression of genes associated with anxiety. Studies also describe effects on serotonin metabolism and on the balance of monoamine turnover in brain regions involved in emotional regulation.

What distinguishes it from benzodiazepine comparators in the preclinical literature is the reported absence of sedation, motor impairment, tolerance and withdrawal in the animal models — a claim that recurs consistently across the Russian work.

The immunomodulatory strand, inherited from tuftsin, covers effects on interleukin expression and immune cell activity, and connects to a smaller literature on antiviral activity.

Selank has been used clinically in Russia, where it is registered for anxiety disorders, and there is published Russian clinical literature reporting anxiolytic effects in generalised anxiety and related conditions, sometimes in comparison with benzodiazepines.

As with Semax, the difficulty is appraisal rather than existence. The clinical work is largely Russian-language, frequently predates modern trial reporting standards, and has not been independently replicated by groups outside that tradition. Trial designs, blinding procedures and statistical handling are often not described in enough detail to assess.

Selank holds no approval from Health Canada, the FDA or the EMA, and has not been through their review processes. Human pharmacokinetic characterisation to Western regulatory standard has not been published.

So there is real human exposure and real clinical claims behind this compound, and an evidence base that cannot be independently verified from outside.

The claim that Selank is anxiolytic without sedation or dependence is the central claim, and it is consistently reported across the animal literature. It is mechanistically plausible, since the compound does not act as a direct GABA-A positive allosteric modulator in the way benzodiazepines do.

What cannot be verified from outside is the clinical part of that claim. Reports of comparable efficacy to benzodiazepines with a better tolerability profile would be significant if independently confirmed, and they have not been.

The claim that a peptide derived from an endogenous immune fragment is inherently safe does not follow. Tuftsin is a natural fragment; Selank is a modified analogue with a stabilising extension designed specifically to persist longer than the natural molecule would.

Claims of nootropic or cognitive enhancement are weaker than the anxiolytic claims. The literature that exists is mostly about anxiety, and reduced anxiety can improve cognitive performance without any direct nootropic action.

Against Semax, the pairing is natural and the distinction matters. Both are Russian-developed, both are short stabilised peptides, both are used intranasally. Semax derives from ACTH(4-10) and its literature centres on BDNF, NGF and neuroprotection. Selank derives from tuftsin and its literature centres on anxiety, GABAergic signalling and immune modulation. They address different endpoints and are not substitutes.

Against benzodiazepines, which the Russian literature uses as the standard comparator, the reported difference is efficacy without sedation, tolerance or withdrawal — the claim that gives the compound its interest, and the one least verifiable from outside.

Against KPV, both trace back to immune-active peptide fragments, but KPV comes from alpha-MSH and acts peripherally on inflammatory signalling, while Selank's principal reported activity is central.

As with Semax, the honest position is that the risk profile is poorly documented by Western standards. Russian clinical use suggests severe acute toxicity is unlikely; systematic pharmacovigilance data comparable to Western reporting does not exist.

A compound that modulates GABAergic and serotonergic signalling has real potential for interaction with psychiatric medication acting on the same systems, and those interactions have not been characterised. This is the most practically important gap.

The immunomodulatory activity inherited from tuftsin is not a side note. Altering interleukin expression and immune cell activity has consequences that have not been mapped in humans over extended exposure, particularly in anyone with autoimmune or immune-mediated conditions.

Intranasal administration carries local considerations independent of the peptide — mucosal irritation with repeated use, and the effects of preservative-containing solutions on nasal tissue.

Long-term consequences of sustained anxiolytic peptide exposure have not been studied.

Selank is a short, comparatively stable peptide and dissolves readily. Because the published protocols are predominantly intranasal, it is often reconstituted at higher concentrations than injectable peptides of similar size.

Introduce bacteriostatic water against the vial wall and swirl gently rather than shaking. Store reconstituted solutions at 2–8 °C protected from light and observe the working window given on this page. Keep unopened lyophilized powder frozen for long-term storage and avoid freeze-thaw cycling.